2-Deoxy-2-[F-18]fluoro-d-glucose Accumulation in Ovarian Carcinoma Cell Lines
- 137 Downloads
To evaluate 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) accumulation in human ovarian carcinoma cell lines compared with control tumor cell lines known to accumulate FDG.
FDG accumulation assays were performed in 15 different ovarian carcinoma cell lines at 1, 2, and 3 hours after incubation with 1 μCi of FDG. Results were compared with FDG accumulation in six different control tumor cell lines. 2-Deoxy-2-[F-18]fluoro-d-glucose accumulation was expressed as counts per minute (cpm) in cells and normalized to initial cpm in medium and total protein content of cell lysates.
FDG accumulation in all 15 ovarian carcinoma cell lines was equal to or higher than 0.0005 ± 8.6 10−5 cpm in cells/cpm in medium/μg protein at all three different time points. In two ovarian carcinoma cell lines (ES-2, poorly differentiated clear cell carcinoma, and OVCAR-3, poorly differentiated papillary adenocarcinoma), FDG accumulation was not statistically, significantly different compared to the control cell line with the highest FDG accumulation (LS 174T human colorectal adenocarcinoma) at two or more time points (P ≥ 0.07). In 2 of 15 (13%) ovarian carcinoma cell lines (OVCAR5 epithelial carcinoma and SKOV3 clear cell carcinoma), FDG accumulation was lower than that in the control cell line with the lowest FDG accumulation (HT-29 human colorectal adenocarcinoma) at one or more time points (P < 0.05).
Most human ovarian carcinoma cell lines showed comparable FDG accumulations with control cell lines known to accumulate FDG. This study lays the foundations for further comparisons with other ovarian cancer cell lines and for other positron emission tomography tracers.
Key wordsFDG accumulation Ovarian carcinoma cell lines Cell uptake study FDG uptake
We would like to thank for the generous support the Canary Foundation and Mr. Don Listwin for funding most of this work. Amelie Lutz was supported in part by the Swiss National Science Foundation. Juergen Willmann was supported in part by the Swiss Foundation of Medical-Biological Grants and Novartis Research Foundation. We would also like to thank support from NIH ICMIC P50 CA114747 (SSG). Furthermore, we would like to thank Dr. David Dick and Dr. Fred Chin in our cyclotron facility for the production of FDG. We would also like to thank Aviva Ventura from Fred Hutchinson Cancer Research Center for her help with the ovarian cancer cell lines.
- 7.Kawahara K, Yoshida Y, Kurokawa T, et al. (2004) Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 28:505–516PubMedCrossRefGoogle Scholar
- 11.Burke MA, Patchefsky AS (2003) Pathology. In: Ozols RF (ed) Ovarian cancer. Hamilton: BC Decker, pp 1–26Google Scholar
- 18.Freshney RI (2005) Biology of cultured cells. In: Culture of animal cells, 5th edn. Hoboken: Wiley, pp 31–42Google Scholar
- 25.Kurokawa T, Yoshida Y, Kawahara K, et al. (2004) Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:926–932PubMedCrossRefGoogle Scholar